The generic name of the drug Belimumab for Injection is a monoclonal antibody analog used clinically for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy. Belimumab for Injection is indicated primarily for adult patients with active, autoantibody-positive systemic lupus erythematosus who continue to have high disease activity on the basis of conventional therapy. Adverse reactions to the use of this drug include viral upper respiratory tract infection, bronchitis, diarrhea, hypotension, angioedema, rash, pruritus, dyspnea, bradycardia, myalgia, arthralgia, and fever. Whether to use the drug also need clinicians according to the degree of the patient’s condition comprehensive judgment, the use of the process to follow the guidance of professional doctors, to avoid blind use caused by the occurrence of adverse events.